Siconazole Capsule (Itraconazole)

Adult dosage

To increase absorption, it is preferable to administer this medicine immediately after a meal. The capsule must be swallowed whole. 1. Short-term treatment This medicine continues to exert a therapeutic effect in skin tissue even after treatment is discontinued. Therefore, it is preferable to assess the final clinical and mycological response 2～4 weeks after completion of the prescribed treatment. 1) Vulvovaginal candidiasis: Administer itraconazole 200 mg twice daily (morning and evening) for 1 day, or 200 mg once daily for 3 days. 2) Tinea versicolor: Administer 200 mg once daily for 7 days. 3) Tinea corporis, tinea cruris: Administer 100 mg once daily for 15 days. 4) Tinea manuum (interdigital), tinea pedis (interdigital): Administer 100 mg once daily for 15 days. 5) Tinea manuum (palmar), tinea pedis (plantar): Administer 100 mg once daily for 30 days or 200 mg twice daily for 7 days. 6) Oral candidiasis: Administer 100 mg once daily for 15 days. 7) Fungal keratitis: Administer 200 mg once daily for 21 days. 2. Onychomycosis 1) Pulse therapy Administer 200 mg twice daily for 1 week, followed by a 3-week treatment-free period; this constitutes one cycle. Administer up to 2 cycles for infection of the fingernails only and up to 3 cycles for infection of the toenails. Dosing schedule for onychomycosis by site: Toenails (with or without concurrent fingernail infection): 1 week on treatment, 2 weeks off treatment, 3 weeks on treatment, 4 weeks off treatment, 5 weeks on treatment. Fingernails: 1 week on treatment, 2 weeks off treatment, 3 weeks on treatment. 2) Continuous therapy Administer 200 mg once daily for 3 months. After treatment ends, the therapeutic effect continues for 3 months for fingernails and 6 months for toenails. 3. Systemic fungal infections In patients with impaired immune function, such as those with neutropenia, AIDS, or organ transplantation, the oral bioavailability of this medicine may be reduced; therefore, increase the dose twofold if necessary. Aspergillosis: 200mg once daily, with an average treatment duration of 2~5 months. For invasive or disseminated disease, increase to 200mg twice daily. Candidiasis: 100~200mg once daily, with an average treatment duration of 3 weeks~7 months. Cryptococcal meningitis: 200mg twice daily, with an average treatment duration of 2 months~1 year. Maintenance therapy (for patients with AIDS only): 200mg once daily. Paracoccidioidomycosis: 100mg once daily, with an average treatment duration of 6 months. There are no efficacy data for this dosage regimen in the treatment of paracoccidioidomycosis in ADIS patients. 1 The duration of treatment should be adjusted according to clinical response. 2 The duration of treatment should depend on immune recovery.

This medication can be life-threatening in patients with poor heart function, so it should not be used in patients with a history of congestive heart failure. If symptoms of heart failure develop while taking this medication, it should be discontinued immediately. Patients who have had an allergic reaction to this drug or have specific heart conditions should not take this medication. Additionally, this drug may interact with several other medications, so if you are taking other medications, you must consult your doctor or pharmacist. It is advisable for pregnant women, women who may become pregnant, and nursing mothers to avoid using this medication. Patients with compromised liver or kidney function should periodically monitor liver function tests and kidney function while taking this drug, and dosage adjustments may be necessary. Caution is needed for patients with weakened immune systems or certain conditions, as the efficacy of this medication may vary. Rarely, it can cause side effects such as headache, nausea, abdominal pain, liver dysfunction, skin rashes, so any unusual symptoms should prompt immediate consultation with healthcare professionals. Heart-related side effects may occur, so patients with heart disease need regular monitoring. Dizziness or vision impairment may occur while taking this medication, so caution is needed when driving or operating machinery. There is no specific antidote for overdose, so it is important to adhere to the prescribed dosage and keep it out of the reach of children.

Decreased myocardial contractility, heart failure, headache, nausea, abdominal pain, rhinitis, sinusitis, upper respiratory tract infection, leukopenia, hypersensitivity, dysgeusia, sensory impairment, sensory abnormalities, tinnitus, constipation, diarrhea, dyspepsia, flatulence, vomiting, liver dysfunction, hyperbilirubinemia, itching, rash, urticaria, frequent urination, erectile dysfunction, menstrual disorders, edema, granulocytopenia, thrombocytopenia, anaphylactic reaction, hyperglycemia, hyperkalemia, hypokalemia, hypomagnesemia, confusion, peripheral neuropathy, dizziness, drowsiness, tremors, heart failure, left ventricular failure, tachycardia, hypertension, hypotension, pulmonary edema, speech disorder, cough, gastrointestinal disturbance, liver failure, hepatitis, jaundice, erythematous rash, hyperhidrosis, myalgia, arthralgia, renal impairment, urinary incontinence, generalized edema, facial edema, chest pain, fever, pain, fatigue, chills, increased alanine aminotransferase, increased aspartate aminotransferase, increased serum alkaline phosphatase, increased lactate dehydrogenase, increased serum urea, increased gamma-glutamyl transferase, increased liver enzymes, abnormal urinalysis, leukocytosis, eosinophilia, anemia, vascular edema, serum sickness, angioedema, anaphylaxis, anaphylactic shock, allergic reaction, double vision, vision impairment, hearing loss, ventricular extrasystole, atrioventricular block, palpitations, increased intestinal motility, belching, glossitis, stomatitis, abdominal and lumbar pain, pancreatitis, elevated serum total protein, elevated total bilirubin, elevated LAP, anorexia, lethargy, brown urine, mucocutaneous syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, Riel syndrome, erythema multiforme, alopecia, photosensitivity reaction, exfoliative dermatitis, leukocytoclastic vasculitis, acute generalized exanthematous pustulosis, elevated BUN, positive urinary protein reaction, positive urinary glucose reaction, decreased libido, drowsiness, shoulder stiffness, insomnia, chest pain, elevated serum triglyceride levels, heat sensation, elevated serum uric acid levels, elevated serum potassium levels, serum sickness, angioedema, anaphylactic reaction, hypertriglyceridemia, tremors, vision impairment, transient hearing loss, permanent hearing loss, congestive heart failure, dyspnea, significant hepatotoxicity, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, exfoliative dermatitis, leukocytoclastic vasculitis, increased serum creatine phosphokinase

This medication should be stored in a tightly closed container to prevent air exposure and kept at room temperature between 1 to 30 degrees Celsius. This ensures the maintenance of its efficacy and prevents degradation.

Appearance

A hard capsule with a blue upper part and a pink lower part filled with white or grayish round pellets

Package unit

30 capsules/bottle, 100 capsules/bottle